As of April 1, 2020, a new service was added to the EBM (German Uniform Evaluation Standard). It will be used for reimbursement of a genetic test that is necessary before the administration of the drug for the treatment of multiple sclerosis with selective sphingosine-1-phosphate receptor modulator (Mayzent).
Mayzent (brand name of siponimod) is used for progressive multiple sclerosis treatment and is known to slow the progression of the disease. In connection with the early benefit assessment of the Federal Joint Committee (G-BA), testing of the Mayzent revealed a need for adjustment in the EBM.
As of April 1, 2020, the fee order item (GOP) 32866 is added to the EBM. With this new GOP, the examination of the alleles CYP2C9 * 1, * 2, and * 3 of the CYP2C9 gene is mapped. This examination is necessary because the patient's CYP2C9 metabolic status must be known before the administration of the active ingredient siponimod.
The GOP 32866 is valued at €82 and will initially receive a limited extrabudgetary remuneration for two years. The Evaluation Committee will then review the financing.
The full details in German can be found here
. The corresponding decision of the Evaluation Committee can be found here
to our newsletter delivered every second week not to miss important reimbursement information.